معرفی
Mojtaba Akhtari, MD is a Professor of Medicine at the School of Medicine, Loma Linda University. His research focuses on hematologic malignancies, including leukemia, lymphoma, and myeloproliferative disorders. He has authored over 124 peer-reviewed publications and holds two notable awards: the Award for Humanism in Medicine (2007) and the Faculty Teaching Award (2015).
Dr. Akhtari’s research interests include novel therapies for blood cancers, clinical trial advancements, and outcomes analysis in hematologic diseases. His work emphasizes translational research, such as evaluating the efficacy and safety of targeted agents like acalabrutinib and inotuzumab. He also investigates complications of treatments, including sinusoidal congestion from inotuzumab and racial disparities in cancer outcomes during the pandemic.
His recent studies highlight the clinical and molecular characterization of hematologic disorders. For example, he proposed a new clinical entity (Calicheamicin syndrome) linked to inotuzumab therapy and analyzed CNS prophylaxis strategies in diffuse large B-cell lymphoma. His work spans case reports, meta-analyses, and large-scale observational studies, reflecting his commitment to advancing patient care through evidence-based practices.
In grants, he leads or collaborates on multiple clinical trials (e.g., SWOG, NRG, and industry-sponsored studies) targeting therapies for lymphoma, leukemia, and solid tumors. His involvement in trials such as the ANVIL study for lung cancer and trials of novel agents like sapanisertib underscores his role in advancing oncology treatments.
Dr. Akhtari’s academic contributions extend to mentoring through grants and institutional projects, including retrospective analyses of clinical practices and biomarker research at Loma Linda Medical Center.
